Centessa posted a Q2 2025 net loss of $50.3M, driven by increased R&D expenses as multiple orexin receptor 2 (OX2R) agonist trials progressed. Cash and investments remained strong at $404.1M, supporting operations into mid-2027.

In Q4 2024, Centessa reported no revenue and a net loss of $111.3 million, a significant increase from the $36.8 million loss in Q4 2023. The loss was driven by a $34.1 million non-recurring charge related to debt extinguishment and a $31.5 million charge related to the discontinued SerpinPC program. R&D expenses rose to $60.9 million and G&A expenses reached $13.7 million. Adjusted EPS excluding the debt extinguishment loss was -$0.58 + $0.26 = -$0.32.

Centessa Pharmaceuticals reported a net loss of $38.0 million for the first quarter of 2024. The company's cash runway is expected to extend into mid-2026, supported by a recent public offering.

Centessa Pharmaceuticals reported a net loss of $36.8 million for the fourth quarter of 2023, with research and development expenses at $29.7 million and general and administrative expenses at $12.3 million. The company's cash, cash equivalents, and short-term investments totaled $256.5 million as of December 31, 2023, expected to fund operations into 2026.

Centessa Pharmaceuticals reported its third quarter 2023 financial results, with a net loss of $38.6 million. The company's cash, cash equivalents, and short-term investments totaled $281.3 million, expected to fund operations into 2026.

Centessa Pharmaceuticals reported its financial results for the second quarter ended June 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $303.6 million as of June 30, 2023, with a net loss attributable to ordinary shareholders of $24.9 million for the second quarter.

Centessa Pharmaceuticals reported a net loss of $50.7 million for the first quarter of 2023. The company's cash, cash equivalents, and short-term investments totaled $346.2 million as of March 31, 2023, expected to fund operations into 2026.

Centessa Pharmaceuticals reported a net loss of $43.2 million for the fourth quarter ended December 31, 2022, and cash and cash equivalents of $393.6 million as of December 31, 2022, which is expected to fund operations into 2026.

Centessa Pharmaceuticals reported a net loss of $53.9 million for the third quarter of 2022, with cash and cash equivalents of $444.8 million as of September 30, 2022. The company is advancing its pivotal program for SerpinPC, planning to present Phase 2a OLE study data at ASH, and on track to submit the IND for LB101 in late 2022. The cash runway is expected to fund operations into 2026.

Centessa Pharmaceuticals reported its Q2 2022 financial results, highlighting the advancement of its rare diseases and immuno-oncology pipeline. The company is on track to initiate registrational studies for SerpinPC for Hemophilia B in the second half of the year and plans to initiate clinical trials with LB101 for solid tumors after an IND filing later this year. However, they discontinued development of ZF874 following an adverse event.

Centessa Pharmaceuticals reported first quarter 2022 financial results, highlighting the advancement of its rare disease and immuno-oncology portfolio towards its '4x24' goal. The company's cash and cash equivalents were $544.5 million as of March 31, 2022, providing an operational cash runway to mid-2024.

Centessa Pharmaceuticals reported cash and cash equivalents of $595.1 million as of December 31, 2021. The company is focusing on rare disease and immuno-oncology assets, with SerpinPC registration studies planned for 2H 2022 and LB101 preclinical data expected at ASCO 2022.

Centessa Pharmaceuticals reported a net loss of $40.2 million for the quarter ended September 30, 2021. The company's cash and cash equivalents were $578.8 million as of September 30, 2021, and pro forma cash and cash equivalents were $653.4 million, inclusive of the net proceeds from the first tranche received under the Oberland Agreement on October 4, 2021.

Centessa Pharmaceuticals announced second quarter 2021 financial results, highlighting the successful completion of an initial public offering, which raised gross proceeds of $379.5 million. The company is advancing its portfolio of 16 clinical and preclinical programs and has strengthened its leadership team with key industry executives.